142 related articles for article (PubMed ID: 11865635)
1. [Development of a Japanese version of the FLIE].
Satou A; Yamazaki T; Nukariya N; Nakamachi M; Shimada K; Matsukawa M; Kurihara M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):281-91. PubMed ID: 11865635
[TBL] [Abstract][Full Text] [Related]
2. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.
Decker GM; DeMeyer ES; Kisko DL
J Support Oncol; 2006 Jan; 4(1):35-41, 52. PubMed ID: 16444851
[TBL] [Abstract][Full Text] [Related]
3. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
4. Measuring chemotherapy-induced nausea and emesis.
Martin CG; Rubenstein EB; Elting LS; Kim YJ; Osoba D
Cancer; 2003 Aug; 98(3):645-55. PubMed ID: 12879484
[TBL] [Abstract][Full Text] [Related]
5. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall.
Martin AR; Pearson JD; Cai B; Elmer M; Horgan K; Lindley C
Support Care Cancer; 2003 Aug; 11(8):522-7. PubMed ID: 12827483
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
7. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' quality of life: An Arabic version of the Functional Living Index-Emesis.
Alhammad AM; Alkhudair N; Alzaidi R; Almosabhi LS; Aljawadi MH
J Oncol Pharm Pract; 2022 Apr; 28(3):535-541. PubMed ID: 33645326
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of EORTC QLQ-C30 questionnaire in patients undergoing in-hospital chemotherapy for gastrointestinal cancer in Japan.
Kato J; Nagahara A; Iijima K; Yoshimura M; Osada T; Yoshizawa T; Watanabe S
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S268-72. PubMed ID: 19120910
[TBL] [Abstract][Full Text] [Related]
9. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
10. Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy.
Kurihara M; Shimizu H; Tsuboi K; Kobayashi K; Murakami M; Eguchi K; Shimozuma K
Psychooncology; 1999; 8(4):355-63. PubMed ID: 10474853
[TBL] [Abstract][Full Text] [Related]
11. Quality of life consequences of chemotherapy-induced emesis.
Lindley CM; Hirsch JD; O'Neill CV; Transau MC; Gilbert CS; Osterhaus JT
Qual Life Res; 1992 Oct; 1(5):331-40. PubMed ID: 1299465
[TBL] [Abstract][Full Text] [Related]
12. Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European study.
Grassi L; Berardi MA; Ruffilli F; Meggiolaro E; Andritsch E; Sirgo A; Caruso R; Juan Linares E; Bellé M; Massarenti S; Nanni MG;
Psychother Psychosom; 2015; 84(6):339-47. PubMed ID: 26402426
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
[TBL] [Abstract][Full Text] [Related]
14. [Management of nausea, vomiting and anorexia due to anticancer agents].
Shimada K; Taguchi S
Gan To Kagaku Ryoho; 2003 Jun; 30(6):760-4. PubMed ID: 12852341
[TBL] [Abstract][Full Text] [Related]
15. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Ishida T; Kusaba T; Hayakawa H
Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
[TBL] [Abstract][Full Text] [Related]
16. [The development of a new QOL Questionnaire on chemotherapy - induced emesis and vomiting--investigation of reliability and validity. Group for Investigation of QOL Questionnaire for Anti-Emetics Used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative study].
Ishihara Y; Nukariya N; Kobayashi K; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H
Gan To Kagaku Ryoho; 1996 May; 23(6):745-55. PubMed ID: 8645026
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
Matsuda Y; Okita K; Furuhata T; Kutomi G; Yamashita K; Sato Y; Takimoto R; Hirata K
Support Care Cancer; 2015 Nov; 23(11):3331-9. PubMed ID: 26003425
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the 3-day recall period for the Functional Life Index-Emesis (FLIE).
Wan BA; Drost L; Ganesh V; Zhang L; Yee C; Tsao M; Barnes E; Pasetka M; DeAngelis C; Chow E
Ann Palliat Med; 2018 Oct; 7(4):393-403. PubMed ID: 30180722
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of chemotherapy-induced nausea and vomiting(CINV)using MASCC antiemesis tool].
Yamaguchi M; Ogawa T; Watanabe M; Anami S; Kamigaki S; Nishikawa N; Ono T; Furukawa H
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1691-6. PubMed ID: 19838029
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced nausea and vomiting: state of the art in 2006.
Schwartzberg L
J Support Oncol; 2006 Feb; 4(2 Suppl 1):3-8. PubMed ID: 16499138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
